Raynaud Phenomenon Clinical Trial
Official title:
A Multicenter Observational Pilot Study on the Use of Tadalafil Delivra Cream in the Treatment of Raynaud's Phenomenon and Pain Associated With Digital Ulcers
NCT number | NCT03393325 |
Other study ID # | TAD-Sc-0001 |
Secondary ID | |
Status | Withdrawn |
Phase | |
First received | |
Last updated | |
Start date | October 2018 |
Est. completion date | September 2019 |
Verified date | September 2018 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A 4-8 week observational feasibility study of the use of the use of Tadalafil-Delivra in the treatment of Reynaud's Phenomena (RP).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | September 2019 |
Est. primary completion date | June 2019 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Adults of both genders, Age 18 to 75 years. 2. Patients with a confirmed diagnosis of Raynaud's Phenomenon (RP). 3. Written informed consent. 4. The presence of 1 or more digital ulcers (DU), that is not related to calcinosis, anywhere on a finger that is symptomatic for RP- defined as a VAS pain score of =25mm of 100mm Or 1 -3 fingers that are symptomatic for RP under standard of care treatment (SoC). Symptomatic is defined as a VAS pain score of = 25mm of 100mm. 5. Prescribed, but not currently being treated with Tad-Del. 6. Maintenance of a stable background of prescribed treatment for RP including vasodilators, orally administered PDE5i and pain medication. Changes to administration of this concomitant medication will be documented in the case report form (CRF). Exclusion Criteria: 1. Unwilling and/or incapable of adhering to the study procedures and follow-up schedule. 2. Use of other prescribed topical treatment for RP, such as nitrates. 3. Active infection of the index ulcer 4. Calcinosis at the site of the index ulcer 5. Received Iloprost or other prostacyclin treatment in the last 4 months. 6. Unsuitable for study participation as determined by the clinical investigator. |
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Healthcare | Hamilton | Ontario |
Canada | Mount Sinai Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Lawson Health Research Institute | Delivra, Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | VAS-100 of DU & RP severity over the previous week assessed by patient & MD | Visual Analogue Scale (VAS) of the severity of Digital Ulcers (DU) and Raynaud's Phenomenon (RP). The physician (MD) and patient will each independently make their own assessment on a linear 10 cm VAS scale by making a mark on the line with a pen anywhere from the left anchor "0" (indicating no disease at all) to the right anchor "10" (indicating the most severe imaginable). Both the MD and patient will complete an individual scale for RP and DU. The distance of the mark from the left anchor "0" will be recorded in mm, divided by 10 and reported as a value from 0 to 10. A total of 4 VAS scales will be completed. | 28 days [this assessment has a window of an additional 28 days (Day 56) to be completed] | |
Secondary | Change in RP and DU interference in daily activities as measured by VAS-100 in SHAQ. | Visual Analogue Scales for Raynaud's Phenomenon and Digital Ulcer interference in daily activities as measured by the patient. Both assessments are part of the Scleroderma Health Assessment Questionnaire (SHAQ). The patient will make an assessment on the linear VAS scale for each by making a mark on the line with a pen anywhere from the left anchor "Does not limit activities" to the right anchor "Very Severe limitation". The distance of the mark from the left to the right anchor will be measured in mm, divided by 10 and reported as a value from 0 to 10. There are two scales: 1 for Raynaud's Phenomena and the other for Digital Ulcer. | 28 days [this assessment has a window of an additional 28 days (Day 56) to be completed] | |
Secondary | changes in the use of concurrent RP therapy and pain medications in patients treated with Tad-Del. | Concomitant medication use at the end of treatment (day 28-56) will be compared with concomitant medication use at baseline with respect to daily dose administered. | 28 days [this assessment has a window of an additional 28 days (Day 56) to be completed] | |
Secondary | All adverse Event experienced by the patient during study participation (1st to last visit) will be recorded. | Adverse events will be summarized and reported at the end of treatment. | 28 days [this assessment has a window of an additional 28 days (Day 56) to be completed] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03749577 -
Nutritional Strategies to Increase Nitric Oxide Signaling in Raynaud's Phenomenon
|
N/A | |
Completed |
NCT03699436 -
Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon
|
N/A | |
Enrolling by invitation |
NCT06291142 -
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
|
||
Recruiting |
NCT03984422 -
Application for Monitoring and Evaluation of Raynaud's Phenomenon
|
||
Recruiting |
NCT04015193 -
Follow-up of SPTS in Patients With Raynaud's Phenomenon
|
||
Not yet recruiting |
NCT03972566 -
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
|
||
Completed |
NCT04854850 -
Apollo Device for Fatigue in Systemic Sclerosis
|
N/A | |
Completed |
NCT03129178 -
Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon
|
N/A | |
Completed |
NCT04388176 -
Cold Challenge With C21 in RP
|
Phase 2 | |
Completed |
NCT01280266 -
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
|
Phase 2/Phase 3 | |
Completed |
NCT04644523 -
Dermoscopy in Primary Raynaud's Phenomenon
|
||
Completed |
NCT03094910 -
Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon
|
N/A | |
Recruiting |
NCT05204784 -
Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
|
N/A | |
Recruiting |
NCT05125029 -
Botulinum Toxin in Raynaud's Phenomenon
|
Phase 4 | |
Terminated |
NCT03639766 -
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
|
Phase 4 | |
Withdrawn |
NCT04898036 -
Phototherapy For Treatment Of Raynaud's Phenomenon
|
N/A | |
Terminated |
NCT03869008 -
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
|
N/A | |
Recruiting |
NCT01347008 -
Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
|
Phase 3 |